In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) Drug Master File in Korea (Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate). The MFDS reviews the Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) KDMF as part of the drug registration process and uses the information provided in the Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) KDMF to evaluate the safety and efficacy of the drug.
After submitting a Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Novadelox (18% benzoyl peroxide, 78% calcium sulphate, 4% magnesium carbonate) suppliers with KDMF on PharmaCompass.